Biogen Idec

  • 601 Pennsylvania Avenue NW
    Suite 720
    Washington, DC 20004
  • 202-383-1440

For more than 35 years, Biogen Idec has been helping to improve the lives of people living with serious medical conditions. Since our founding in 1978, we’ve produced therapies for diseases that affect hundreds of thousands of people around the world.

The company was founded in Zurich, Switzerland by scientists who were the first to clone and express interferon, the monoclonal antibody that led to the development of our first multiple sclerosis (MS) therapy, AVONEX®. A pioneer in the biotechnology industry and one of the first biotech companies, Biogen Idec now has the world’s leading portfolio of MS therapies and in 2014 introduced new treatments for hemophilia A and B, bringing the first innovation to patients in almost two decades.

Today, Biogen Idec’s research efforts are built on understanding the underlying biology of complex diseases with a focus on developing therapies for patients with serious illnesses that currently have few, if any, treatment options. Beyond biology, we are using a significant number of major drug discovery and development platforms to identify and bring new treatments to patients. We have only started to tap the potential of science to address serious medical conditions. As we look to the future, our success will always be measured by the answer to a simple question: Have we truly made a difference in the lives of the patients we serve?